Abstract
Induced pluripotent stem cells (iPSCs) were first created in 2006 when it was shown that four gene factors could be used to reprogramme somatic cells to a stem cell-like state. Using this protocol, scientists could have a large, ethical supply of stem cells for research. This article considers some of the uses of iPSCs in developing degenerative disease therapies and some of the hurdles yet to be overcome before iPSCs can be used clinically.
Stem cells are undifferentiated pluripotent cells that can give rise to any of the body’s cells. There are many different types of stem cells in the body, but they all share major characteristics including clonality and the ability to self-renew (Evans and Kaufman, 1981). There are numerous benefits of using stem cells in research including scientists’ ability to manipulate them into the desired differentiated cell type. Embryonic stem cells (ESCs), especially, have enabled research into degenerative human diseases and offer potential cures for many disease types. However, there are numerous ethical issues associated with ESCs due to their provenance. Differentiated adult tissue cells (somatic cells) have recently been shown to be reprogrammable, creating induced pluripotent stem cells (iPSCs) (Takahashi and Yamanaka, 2006). This process avoids many of the ethical issues associated with ESCs. This article will discuss the recent progresses made with using iPSCs and the challenges yet to be overcome.
The importance of stem cells in regenerative disease models
Degenerative diseases are characterised by the progressive loss of particular cell types. Some well known examples include Alzheimer’s disease, Parkinson’s disease and multiple sclerosis. However, despite the frequency of degenerative diseases, research into degeneration has been hindered due to the lack of representative in vitro models. So far, research has relied on the pluripotent characteristics of ESCs and has shown that lab-grown ESCs have the potential to replace lost tissues, for example by differentiating into brain, nerve and bone tissues amongst others (Lin, 2011; Handschel et al., 2011).
In spite of the advantages of ESCs, there are limitations to their use. ESCs cannot be cultured in sufficient quantities for regenerative medicine, partly due to their provenance: obtaining cells from embryos raises major ethical issues.
As a consequence, recent research has focused on finding alternative methods of generating representative disease models. Many barriers have arisen such as mature neurones not being able to divide, immortalised cell lines not being truly pluripotent and adult stem cells already being committed to a particular cell type. In this case, the cells rarely survived the neuronal differentiation process (Peng and Zeng, 2011).
The discovery of iPSCs
In 2006, it was discovered that gene factors could be used to induce somatic cell reprogramming. It was shown that any adult mouse tissue cell can be reprogrammed to an iPSC using a set of four gene factors (Takahashi and Yamanaka, 2006). Just a year later, it was shown that the same four gene factors could also be used to genetically reprogramme human somatic cells (Takahashi et al., 2007). The four factors used by Takahashi and Yamanaka were Oct4, Sox2, Klf4 and c-Myc (OSKM), though later work successfully substituted Klf4 and c-Myc with Lin28 and Nanog respectively (giving OSLN).
This technique enabled scientists to culture iPSCs from any somatic cell, providing an unlimited supply of stem cells. Additionally, ESCs and iPSCs have been shown to share many characteristics including morphology, proliferation, gene expression and surface antigens (Takahashi et al., 2007; Kolios and Moodley, 2013). The reprogramming process bypasses the ethical issues and the quantitative limitations of ESCs. Disease-specific models can now be cultured, overcoming many limitations of previously available systems (Peng and Zeng, 2011).
Brief overview of the steps for reprogramming
Reprogramming is initiated by introducing the four factors, OSKM or OSLN, into mature adult somatic cells. These factors bind in a specific order to their targets and induce the cellular stress response to viruses and oncogenes. This in turn recruits p53, which is crucial in ensuring that only cells with genomic integrity survive to the pluripotent stage. It has been shown that c-Myc is fundamental in both the early stages of translation and in decreasing expression of mouse embryonic fibroblasts (MEF)-enriched miRNAs, which are barriers to reprogramming (Yang and Rana, 2013).
The next step in reprogramming is mesenchymal-to-epithelial (MET) transition, which is essential for some cells to start their de-differentiation process. During MET transition, the reprogrammed cells start to display pluripotency markers. Of these markers, SSEA-1 is the first to be expressed and indicates potential iPSCs. The expression of additional factors mark a successful and complete reprogramming (Yang and Rana, 2013).
The potential for iPSCs
The unlimited supply and differentiation capacities of iPSCs means models of many diseases can now be created for research. These models enable scientists to gain a better understanding of the mechanisms of diseases, potentially leading to cell-based therapy.
Another major clinical opportunity for iPSCs is tolerance to treatment. Somatic cells can be taken and reprogrammed from the person requiring treatment, meaning a personalised diagnosis and the conservation of their specific cell markers. This should prevent immune rejection (Park et al., 2008). Disease models are expected to be more accurate with iPSCs; as the cells are taken directly from the diseased patients, the genetic makeup of the disease can be conserved (Dimos et al., 2008).
Drug development is another area made easier with iPSCs. Reprogramming means large quantities of pluripotent stem cells. iPSCs can be created as long as researchers have access to adult somatic cells. Drug development requires numerous assays and an increase in the quantity of pluripotent stem cells is invaluable for progress. Furthermore the reprogramming protocol is fairly straightforward (Oh et al., 2012). However, it should be noted that, at present, it is not yet known how iPSCs would behave in a clinical environment compared to ESCs (Kolios and Moodley, 2013).
Limitations to iPSC use: safety concerns
The main iPSC safety concern is genetic stability. The use of retroviral vectors and oncogenes such as c-Myc and Klf4 are a major cause of concern for clinical studies. The transcription factors are typically introduced into the somatic cells using vectors, generating a possibility of cancer formation (Kolios and Moodley, 2013; Okita et al., 2007).
There are new techniques emerging that prevent genetic instability. Reprogramming can be achieved using just two of the four gene factors mentioned. Oct4 and Soc2 can induce reprogramming without the other oncogenic factors in the presence of a histone deacetylase inhibitor (Huangfu et al., 2008).
Alternatively, microRNAs, along with Oct4, Sox2 and Klf4, can induce reprogramming and actually increase the rate of efficiency with respect to the OSKM factors alone. New viral vectors and recombinant proteins have also been considered as alternatives to the OSKM factors (Ebben et al., 2011).
Limitations to iPSC use: supply concerns
As research progresses, the main provenance of iPSCs will likely be from diseased patients’ somatic cells. This will make iPSCs much more easily available than ESCs, but will not necessarily solve supply problems completely. Reprogramming is not an efficient process, and many somatic cells do not complete it (Polo et al., 2012). Stem cells are also known for their delicacy and specific culture requirements. A lot of laboratory equipment is too abrasive for stem cells and is susceptible to regularly blocking. This said, recent progress in automated liquid handlers design means that robots capable of handling stem cells do now exist (e.g. Redd&Whyte’s Preddator).
Conclusions
Since the first creation of iPSCs in 2006, research has come a long way. We are now able to create patient-specific and disease-specific degenerative disease models. However, before clinical trials with iPSCs can occur, some important barriers remain to be overcome. The full potential of iPSCs to improve our understanding of diseases is not yet clear, but progress in this field is clearly happening quickly.
About The Author: Clare Stewart is a biochemistry student at the University of Manchester, she has written this post on behalf of Redd & Whyte
References:
Dimos, J. T., Rodolfa, K. T., Niakan, K. K., Weisenthal, L. M., Mitsumoto, H., Chung, W., Croft, G. F., Saphier, G., Leibel, R., Goland, R., Wichterle, H., Henderson, C. E. & Eggan, K. (2008) Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons. Science, 321(5893), 1218-1221.
Ebben, J. D., Zorniak, M., Clark, P. A. & Kuo, J. S. (2011) Introduction to Induced Pluripotent Stem Cells: Advancing the Potential for Personalized Medicine. World Neurosurgery, 76(3-4), 270-275.
Evans, M. J. & Kaufman, M. H. (1981) Establishment In Culture Of Pluripotential Cells From Mouse Embryos. Nature, 292(5819), 154-156.
Handschel, J., Naujoks, C., Depprich, R., Lammers, L., Kubler, N., Meyer, U. & Wiesmann, H. P. (2011) Embryonic stem cells in scaffold-free three-dimensional cell culture: osteogenic differentiation and bone generation. Head & Face Medicine, 7.
Huangfu, D. W., Osafune, K., Maehr, R., Guo, W., Eijkelenboom, A., Chen, S., Muhlestein, W. & Melton, D. A. (2008) Induction of pluripotent stem cells from primary human fibroblasts with only Oct4 and Sox2. Nature Biotechnology, 26(11), 1269-1275.
Kolios, G. & Moodley, Y. (2013) Introduction to Stem Cells and Regenerative Medicine. Respiration, 85(1), 3-10.
Lin, S. L. (2011) Concise Review: Deciphering the Mechanism Behind Induced Pluripotent Stem Cell Generation. Stem Cells, 29(11), 1645-1649.
Oh, Y. Z., Wei, H. M., Ma, D. R., Sun, X. M. & Liew, R. (2012) Clinical applications of patient-specific induced pluripotent stem cells in cardiovascular medicine. Heart, 98(6), 443-449.
Okita, K., Ichisaka, T. & Yamanaka, S. (2007) Generation of germline-competent induced pluripotent stem cells. Nature, 448(7151), 313-U1.
Park, I. H., Lerou, P. H., Zhao, R., Huo, H. G. & Daley, G. Q. (2008) Generation of human-induced pluripotent stem cells. Nature Protocols, 3(7), 1180-1186.
Peng, J. & Zeng, X. M. (2011) The role of induced pluripotent stem cells in regenerative medicine: neurodegenerative diseases. Stem Cell Research & Therapy, 2.
Polo, J. M., Anderssen, E., Walsh, R. M., Schwarz, B. A., Nefzger, C. M., Lim, S. M., Borkent, M., Apostolou, E., Alaei, S., Cloutier, J., Bar-Nur, O., Cheloufi, S., Stadtfeld, M., Figueroa, M. E., Robinton, D., Natesan, S., Melnick, A., Zhu, J. F., Ramaswamy, S. & Hochedlinger, K. (2012) A Molecular Roadmap of Reprogramming Somatic Cells into iPS Cells. Cell, 151(7), 1617-1632.
Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K. & Yamanaka, S. (2007) Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell, 131(5), 861-872.
Takahashi, K. & Yamanaka, S. (2006) Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell, 126(4), 663-676.
Yang, C. S. & Rana, T. M. (2013) Learning the molecular mechanisms of the reprogramming factors: let's start from microRNAs. Molecular Biosystems, 9(1), 10-17.
- Regenerative medicine UKRI - UK Research and Innovation - December 10th, 2023
- What Is Regenerative Medicine? | Goals and Applications | ISCRM - December 2nd, 2023
- What Is Regenerative Medicine? | Mass General Brigham - December 2nd, 2023
- Advancing Safe and Effective Regenerative Medicine Products - March 20th, 2023
- Can This Companys Research Help Transform Regenerative Medicine As Its ... - December 18th, 2022
- Regenerative Medicine in Pharma Market Size, Share and Trends Analysis by Region, Drug Class, Route of Administration, and Segment Forecast, 2022-2027... - December 10th, 2022
- Stem Cells Applications in Regenerative Medicine and Disease ... - November 16th, 2022
- Neuroregeneration - Center for Regenerative Biotherapeutics - Mayo ... - November 16th, 2022
- Journal of Immunology and Regenerative Medicine - ScienceDirect - November 16th, 2022
- A Look At Some Of The Companies Innovating In the Cutting-Edge ... - November 16th, 2022
- Regenerative Medicine Advanced Therapy Designation | FDA - October 29th, 2022
- Packing More Punch for Regenerative Medicine and Cell and Gene Therapies - Inside Precision Medicine - October 29th, 2022
- Brush Up: Tissue Engineering and Regenerative Medicine - The Scientist - October 21st, 2022
- The Alliance for Regenerative Medicine Announces Election of 2023 Officers, Executive Committee, and Board of Directors - GlobeNewswire - October 13th, 2022
- Husband and Wife Team Bring Regenerative Medicine Clinic to Jackson - Franchising.com - October 13th, 2022
- Hundreds run for regenerative medicine research at the 2022 TCS London Marathon - British Heart Foundation - October 13th, 2022
- Frequency Therapeutics Completes Enrollment of Phase 2b Study of FX-322 for the Treatment of Sensorineural Hearing Loss - Yahoo Finance - October 13th, 2022
- SANUWAVE's Energy First Technology to be Featured in 3 Clinical Posters at Upcoming 2022 Fall Symposium on Advanced Wound Care (SAWC) -... - October 13th, 2022
- 3D Bioprinting Market Size to Touch Valuation of $1.5 Billion by 2028 | Inkjet Technology Generates More than 38% Revenue of Bioprinting Market -... - October 13th, 2022
- QC Kinetix (Columbia) Offers Regenerative Medicine Treatments to Treat Different Types of Physical Pain and Injuries - Yahoo Finance - October 4th, 2022
- Astellas and Pantherna Enter into a New Technology Evaluation Agreement for Research with Expanded Target Organ to Generate mRNA-Based Regenerative... - October 4th, 2022
- Company / An Advance In Vaginal Rejuvenation, Regenerative Medicine And Aesthetic Gynecology - World Nation News - October 4th, 2022
- Performance Rehabilitation and Regenerative Medicine's Dr. Joseph Mejia honored as a Castle Connolly Top Doctor - Jersey's Best - October 4th, 2022
- Teijin, J-TEC, Mitsui Fudosan, and NCC to create a new platform for regenerative medicine innovation - The Worldfolio - October 4th, 2022
- Cell Regeneration Medicine Market to be valued at US$ 34.3 Bn by the end of 2022 | FMI Research - PharmiWeb.com - October 4th, 2022
- Enlivex to Present at the 4th Macrophage-Directed Therapies Summit - Yahoo Finance - October 4th, 2022
- Fracturing bones and traditional views of civil engineering - ASU News Now - October 4th, 2022
- BioMarin Resubmits Biologics License Application (BLA) for Valoctocogene Roxaparvovec AAV Gene Therapy for Severe Hemophilia A to the FDA - PR... - October 4th, 2022
- Organ on a Chip Market - Focus on Products and Technologies - Distribution by Type of Product, Application Area, Purpose, and Key Geographical Regions... - October 4th, 2022
- QC Kinetix (Riverside Parkway) Offers Regenerative Medicine Treatments to Treat Pain and Injuries in Tulsa, OK - Yahoo Finance - September 25th, 2022
- Reprogramming pig cells leads way for new regenerative therapies - National Hog Farmer - September 25th, 2022
- Research Roundup: Regenerative Potential, Long COVID Insights, Immuno-Oncology and More - BioSpace - September 25th, 2022
- Dr. Batcheller's Wellness and Esthetics, Mecca for Regenerative Medicine and Esthetics - Digital Journal - September 25th, 2022
- Organicell Regenerative Medicine, Inc. Announces Expansion of Management Team - Yahoo Finance - September 25th, 2022
- Pfizer and Sangamo Therapeutics Announce Phase 3 Trial of Investigational Gene Therapy for Hemophilia A Has Re-Opened Recruitment - Pfizer - September 25th, 2022
- Neurona Therapeutics Presents Clinical Case Study from First Human Trial of Regenerative Cell Therapy, NRTX-1001, in Adults with Drug-Resistant Focal... - September 25th, 2022
- Center for Breakthrough Medicines (CBM) and jCyte Announce Strategic Partnership to Manufacture jCyte's Innovative Cell Therapy for Treatment of... - September 25th, 2022
- 2022 UK Equine Research Hall of Fame Inductees Announced The Horse - TheHorse.com - September 25th, 2022
- Science on the go: Catch the Veterinary Vertex podcast - American Veterinary Medical Association - September 25th, 2022
- Advanced robotics to address the translational gap in tendon engineering - EurekAlert - September 25th, 2022
- Russ Olsen Makes Multi-Million Dollar Pledge in support of the Robert Morris University Library - Robert Morris University - September 25th, 2022
- Humacyte Expands Board of Directors and Leadership Team with New Appointments - Yahoo Finance - September 25th, 2022
- First time in India: Stem cell therapy to treat knee osteoarthritis - Moneycontrol - September 25th, 2022
- George Church: Learn from COVID and fast-track therapies that reverse aging - Longevity.Technology - September 25th, 2022
- EpiBone CEO and Co-Founder Dr. Nina Tandon Selected to Participate in White House Summit - PR Web - September 25th, 2022
- Krystal Biotech Receives Positive Opinion from EMA Pediatric Committee on the Pediatric Investigation Plan for B-VEC for the treatment of Dystrophic... - September 25th, 2022
- Humacyte Announces Presentations by Ukrainian Surgeons on Use of the Human Acellular Vessel to Treat Wartime Vascular Trauma at the European Society... - September 25th, 2022
- Fertility Supplements And Vitamins For Women: What You Need To Know - Forbes - September 25th, 2022
- CIRM awards UCI $2.7 million to create regenerative medicine training program - UCI News - September 16th, 2022
- Regenerative Medicine Hub at W-S Innovation Quarter keeps growing with new addition - WRAL TechWire - September 16th, 2022
- QC Kinetix (Chandler): The Future of Regenerative Medicine in Arizona - Digital Journal - September 16th, 2022
- Platelet-Rich Plasma: A Promising Regenerative Therapy in Gynecological Disorders - Cureus - September 16th, 2022
- 4 to be inducted into UK Equine Research Hall of Fame - WTVQ - September 16th, 2022
- FACT SHEET: The United States Announces New Investments and Resources to Advance President Bidens National Biotechnology and Biomanufacturing... - September 16th, 2022
- AVITA Medical Achieves Positive Topline Pivotal Trial Results for Treatment of Stable Vitiligo Using the RECELL System - Yahoo Finance - September 16th, 2022
- Cell Culture Media Market worth $10.3 billion by 2026 - Exclusive Report by MarketsandMarkets - GlobeNewswire - September 16th, 2022
- Following some big FDA wins, Carmell Therapeutics plans to go public. Here's why - Technical.ly - September 16th, 2022
- Pharmaceutical Drug Delivery Market is expected to generate a revenue of USD 2,583 Billion by 2030, Globally, at 6.6% CAGR: Verified Market Research -... - September 16th, 2022
- Capstan Therapeutics Launches with $165 Million to Deliver on the Clinical Promise of Precise In Vivo Cell Engineering - Business Wire - September 16th, 2022
- Children's Health will fund pediatric unit at the Texas Health and Human Services Commission UT Southwestern Medical Center psychiatric hospital - UT... - September 16th, 2022
- Cell Line Development Market Projected to Experience a CAGR of 5% from 2022 to 2032, value worth US$ 7.66 Billion | Future Market Insights, Inc. -... - September 16th, 2022
- UB researchers identify new model of cerebral cortex development linked to reelin protein expression - EurekAlert - September 16th, 2022
- NYC Dermatologist, Dr. Julie Russak, launches first Anti-Aging Wellness Program of its kind in the U.S. - PR Web - September 16th, 2022
- About Regenerative Medicine - Center for Regenerative Biotherapeutics ... - September 8th, 2022
- Global Exosome Market Report 2022: Integration into Fields of Liquid Biopsy, Precision Medicine, and Regenerative Medicine Driving Growth -... - September 8th, 2022
- Addressing Diversity Barriers to Regenerative Medicine Free Press of Jacksonville - Jacksonville Free Press - September 8th, 2022
- Looking to buy Mesoblast shares? Here's the latest on where the ASX biotech is at with the FDA - The Motley Fool Australia - September 8th, 2022
- Sernova Announces the Appointment of Daniel Mahony, Ph.D. to its Board of Directors - GlobeNewswire - September 8th, 2022
- 7.5 Million Granted to Collaborative PROTO Project led by Charit to Study Pluri's PLX-PAD Cells for Osteoarthritis Treatment - GlobeNewswire - September 8th, 2022
- Regenerative Medicine Market to Garner Bursting Revenues [+USD 27.29 Billion] with Top Growing Companies During 2022-2029 - eTurboNews | eTN - August 30th, 2022
- ElevateBio Partners with the California Institute for Regenerative Medicine to Accelerate the Development of Regenerative Medicines - Business Wire - August 30th, 2022
- Global Cell Therapy Market to Reach a Capital Expenditure of USD 10.23 billion in 2021 - eTurboNews | eTN - August 30th, 2022
- Therapeutic Solutions International Develops Gene Silencing Therapy for Acute Respiratory Distress Syndrome - BioSpace - August 30th, 2022
- How Astrocytes May Be Able to Help With Brain Repair - Best Health Magazine - August 30th, 2022
- Applied StemCell Announces the Expansion of its cGMP Manufacturing Facility to Support Cell and Gene Therapy - Business Wire - August 30th, 2022
- Scientists just bypassed millions of years worth of evolution in mice - Inverse - August 30th, 2022
- NIAMS Update, Issue 4, 2022 | NIAMS - National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) - August 30th, 2022
- Heart Association fellowship to support research - Binghamton - August 30th, 2022
- Climate change is making the new school year harder in all kinds of ways - Salon - August 30th, 2022
- Global Biomaterials Market to Reach Value of $372.7 Billion by 2028 | Demand For Biomaterials in the Healthcare Industry will Grow by 53% Over the... - August 30th, 2022